RxDoctor Payments Data

Daniel Pearson, MD

Pulmonary Disease · Dayton, OHNPI 1962708552

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $55,930 of the $61,312 with a category attached, or 91.2%. Regeneron Healthcare Solutions, Inc. accounts for 66.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $50,412 and has fallen 100.0% since, to $24 in 2022. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,312in general payments, 2019–2025

Across 68 payments — averaging $901.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$41K
  • Sanofi$20K
  • Veran Medical Technologies, Inc.$790
  • Supernus Pharmaceuticals, Inc.$51
  • Pacira Pharmaceuticals Incorporated$24
  • AbbVie$16

What the payments were for

  • Consulting fees$1,5333%
  • Speaking & faculty fees$55,93091%
  • Travel & lodging$2,6214%
  • Food & beverage$1,2282%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,312 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$50,747
Medicare patients
123
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →